Arena Pharma (ARNA) Moves Higher; Sees European Belviq Approval in H113, All Debt Prepaid
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares are volatile into its presentation at the NewsMakers in the Biotech Industry conference today.
The company sees approval for its weight-loss drug Belviq in the first-half of 2013 and that new drugs are working its way through its pipeline.
Further, the phama commented that it has prepaid all outstanding debts and its balance sheet is strong.
Shares are down about 0.5 percent Friday morning.
The company sees approval for its weight-loss drug Belviq in the first-half of 2013 and that new drugs are working its way through its pipeline.
Further, the phama commented that it has prepaid all outstanding debts and its balance sheet is strong.
Shares are down about 0.5 percent Friday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
- Hunterbrook bullish on Modine Manufacturing (MOD)
- Holcim said to acquire part of James Hardie's EU business
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
